PRAC meeting highlights 25-28 November 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the November 2024 meeting provides an update on the review of doxycycline and the risk of suicidality, in addition to new recommendations to minimise the risk of liver injury associated with the use of Veoza (fezolinetant).